Common Contracts
23 similar Employment Agreement contracts by Jounce Therapeutics, Inc., Bluebird Bio, Inc., Vericel Corp, others
EX-10.12 19 d471930dex1012.htm EX-10.12 EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2020 • Massachusetts
This Employment Agreement (the “Agreement”) is by and between Surface Oncology, Inc. (the “Company”) and Vito Palombella, Ph.D. (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreements and the Equity Documents (each as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement.
EX-10.15 11 d500108dex1015.htm EX-10.15 AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2020 • Massachusetts
This Employment Agreement (“Agreement”) is between bluebird bio, Inc., a Delaware corporation (the “Company”), and David M. Davidson, M.D. (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “IPO”), provided the IPO is consummated prior to December 31, 2013 (the “Effective Date”).
EX-10.3 4 a17-22104_1ex10d3.htm EX-10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2020 • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 15th day of September, 2017, between Vericel Corporation, a Michigan corporation (the “Company”), and Gerard Michel (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 29th, 2018 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (the “Agreement”) is made as of June 28, 2018 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Gaetan Andre Turenne (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 23rd, 2018 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (the “Agreement”) is by and between Surface Oncology, Inc. (the “Company”) and Vito Palombella, Ph.D. (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreements and the Equity Documents (each as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement.
Board (the "Compensation Committee") from time to time (the "Bonus"), with the actual amount of the Bonus, if any, determined based upon the Board or the Compensation Committee’s assessment of achievement of certain pre-determined performance goals....Employment Agreement • March 8th, 2018 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • September 19th, 2017 • Vericel Corp • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 15th day of September, 2017, between Vericel Corporation, a Michigan corporation (the “Company”), and Gerard Michel (the “Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • September 19th, 2017 • Vericel Corp • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 14th day of September, 2017, between Vericel Corporation, a Michigan corporation (the “Company”), and Daniel R. Orlando (the “Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 17th, 2017 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) is made as of the sixth of January, 2017 by and between Jounce Therapeutics, Inc. (the “Company”), and Kim Drapkin, CPA (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Executive and the Company dated August 21, 2015 and the Employment Agreement between the Executive and the Company dated November 12, 2015 (the “Former Employment Agreements”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 17th, 2017 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) is made as of the sixth of January, 2017 by and between Jounce Therapeutics, Inc. (the “Company”), and Richard Murray, Ph.D. (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Executive and the Company dated May 30, 2014 and the Employment Agreement between the Executive and the Company dated January 6, 2016 (the “Former Employment Agreements”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 17th, 2017 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) is made as of the sixth of January, 2017 by and between Jounce Therapeutics, Inc. (the “Company”), and Elizabeth Trehu, M.D. (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Executive and the Company dated October 15, 2015 and the Employment Agreement between the Executive and the Company dated November 3, 2015 (the “Former Employment Agreements”).
EMPLOYMENT AGREEMENTEmployment Agreement • December 30th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the twelth of November, 2015 by and between Jounce Therapeutics, Inc. (the “Company”), and Kim Drapkin (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Employee and the Employer dated August 21, 2015 (the “Former Employment Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • December 30th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the sixth of January, 2016 by and between Jounce Therapeutics, Inc. (the “Company”), and Richard Murray, PhD (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Executive and the Company dated May 30, 2014 (the “Former Employment Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 17th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of November 11, 2016 by and between Jounce Therapeutics, Inc. (the “Company”), and Stephen Farrand (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Employee and the Employer dated September 2, 2016 (the “Former Employment Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 12th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the ninth of December, 2015 by and between Jounce Therapeutics, Inc. (the “Company”), and Anna L. Barry (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Employee and the Employer dated November 26, 2013 and Employment Agreement dated October 7, 2015 (the “Former Employment Agreements”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 12th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the sixth of January, 2016 by and between Jounce Therapeutics, Inc. (the “Company”), and Richard Murray, PhD (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Executive and the Company dated May 30, 2014 (the “Former Employment Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 12th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the twelth of November, 2015 by and between Jounce Therapeutics, Inc. (the “Company”), and Kim Drapkin (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Employee and the Employer dated August 21, 2015 (the “Former Employment Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 12th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the seventh of October, 2015 by and between Jounce Therapeutics, Inc. (the “Company”), and Jigar Raythatha (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Employee and the Employer dated November 27, 2012 (the “Former Employment Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 12th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the seventh of October, 2015 by and between Jounce Therapeutics, Inc. (the “Company”), and Deborah A. Law (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Employee and the Employer dated December 16, 2014 (the “Former Employment Agreement”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 4th, 2013 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is between bluebird bio, Inc., a Delaware corporation (the “Company”), and David M. Davidson, M.D. (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “IPO”), provided the IPO is consummated prior to December 31, 2013 (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 4th, 2013 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is between bluebird bio, Inc., a Delaware corporation (the “Company”), and Mitchell Finer (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “IPO”), provided the IPO is consummated prior to December 31, 2013 (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 4th, 2013 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is between bluebird bio, Inc., a Delaware corporation (the “Company”), and Jeffrey T. Walsh (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “IPO”), provided the IPO is consummated prior to December 31, 2013 (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 4th, 2013 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is between bluebird bio, Inc., a Delaware corporation (the “Company”), and Nick Leschly (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “IPO”), provided the IPO is consummated prior to December 31, 2013 (the “Effective Date”).
